<?xml-stylesheet type="text/xsl" href="ViewNLM-v2.3.xsl"?><!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN" "archivearticle3.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">Allergy Asthma Immunol Res</journal-id><journal-id journal-id-type="publisher-id">AAIR</journal-id><journal-title-group><journal-title>Allergy, Asthma &#x00026; Immunology Research</journal-title></journal-title-group><issn pub-type="ppub">2092-7355</issn><issn pub-type="epub">2092-7363</issn><publisher><publisher-name>The Korean Academy of Asthma, Allergy and Clinical Immunology; The Korean Academy of Pediatric Allergy and Respiratory Disease</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4168/aair.2009.1.1.30</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Association analysis of peroxisome proliferator-activated receptors gamma gene polymorphisms with asprin hypersensitivity in asthmatics</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Oh</surname><given-names>Sun-Hee</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Park</surname><given-names>Se-Min</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Park</surname><given-names>Jong-Sook</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Jang</surname><given-names>An-Soo</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Yong-Mok</given-names></name><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Uh</surname><given-names>Soo-Taek</given-names></name><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Young Hoon</given-names></name><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Choi</surname><given-names>In-Seon</given-names></name><xref ref-type="aff" rid="A4">4</xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Mi-Kyeong</given-names></name><xref ref-type="aff" rid="A5">5</xref></contrib><contrib contrib-type="author"><name><surname>Park</surname><given-names>Byeong Lae</given-names></name><xref ref-type="aff" rid="A6">6</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Shin</surname><given-names>Hyoung-Doo</given-names></name><xref ref-type="aff" rid="A6">6</xref><xref ref-type="aff" rid="A7">7</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Park</surname><given-names>Choon-Sik</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib></contrib-group><aff id="A1"><label>1</label>Genome Research Center for Allergy and Respiratory Disease, Soonchunhyang University, Bucheon Hospital, Bucheon, Korea.</aff><aff id="A2"><label>2</label>Division of Allergy and Respiratory Disease, Soonchunhyang University, Seoul Hospital, Seoul, Korea.</aff><aff id="A3"><label>3</label>Division of Allergy and Respiratory Disease, Soonchunhyang University, Chunan Hospital, Chunan, Korea.</aff><aff id="A4"><label>4</label>Department of Allergy, Chonnam National University Medical School and Research Institute of Medical Sciences, Gwangju, Korea.</aff><aff id="A5"><label>5</label>Department of Internal Medicine, Chungbuk National University, College of Medicine, Cheongju, Korea.</aff><aff id="A6"><label>6</label>Department of Genetic Epidemiology, SNP Genetics, Inc., Seoul, Korea.</aff><aff id="A7"><label>7</label>Department of Life Science, Sogang University, Seoul, Korea.</aff><author-notes><corresp> Correspondence to: Choon-Sik Park, M.D., Ph.D., Division of Allergy and Respiratory Medicine, Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, 1174 Jung-dong, Wonmi-gu, Bucheon 420-021, Korea. Tel: +82-32-621-5105; Fax: +82-32-621-5016; <email>mdcspark@unitel.co.kr</email>, Hyoung-Doo Shin, M.D., Ph.D., Department of Life Science, Sogang University, 1 Shinsu-dong, Mapo-gu, Seoul 121-742, Korea. Tel: +82-2-705-8615; Fax: +82-2-2026-4299; <email>hdshin@sogang.ac.kr</email></corresp></author-notes><pub-date pub-type="ppub"><month>10</month><year>2009</year></pub-date><pub-date pub-type="epub"><day>25</day><month>9</month><year>2009</year></pub-date><volume>1</volume><issue>1</issue><fpage>30</fpage><lpage>35</lpage><history><date date-type="received"><day>26</day><month>6</month><year>2009</year></date><date date-type="accepted"><day>31</day><month>8</month><year>2009</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2009 The Korean Academy of Asthma, Allergy and Clinical Immunology &#x02022; The Korean Academy of Pediatric Allergy and Respiratory Disease</copyright-statement><copyright-year>2009</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec><title>Purpose</title><p>Peroxisome proliferator-activated receptors (PPARs) are transcriptional factors activated by ligands of the nuclear hormone receptor superfamily. The activation of PPAR&#x003b3; regulates inflammation by downregulating the production of Th2 type cytokines and eosinophil function. In addition, a range of natural substances, including arachidonate pathway metabolites such as 15-hydroxyeicosatetranoic acid (15-HETE), strongly promote <italic>PPARG</italic> expression. Therefore, genetic variants of the <italic>PPARG</italic> gene may be associated with the development of aspirin-intolerant asthma (AIA). We investigated the relationship between single nucleotide polymorphism (SNP) of the <italic>PPARG</italic> gene and AIA.</p></sec><sec><title>Methods</title><p>Based on the results of an oral aspirin challenge, asthmatics (n=403) were categorized into two groups: those with a decrease in FEV<sub>1</sub> of 15% or greater (AIA) or less than 15% (aspirin-tolerant asthma, ATA). We genotyped two single nucleotide polymorphisms in the <italic>PPARG</italic> gene from Korean asthmatics and normal controls (n=449): +<italic>34C&#x0003e;G</italic> (Pro12Ala) and +<italic>82466C&#x0003e;T</italic> (His449His).</p></sec><sec><title>Results</title><p>Logistic regression analysis showed that +<italic>82466C&#x0003e;T</italic> and haplotype 1 (CC) were associated with the development of aspirin hypersensitivity in asthmatics (<italic>P</italic>=0.04). The frequency of the rare allele of +<italic>82466C&#x0003e;T</italic> was significantly higher in AIA patients than in ATA patients in the recessive model [<italic>P</italic>=0.04, OR=3.97 (1.08-14.53)]. In addition, the frequency of <italic>PPARG</italic> haplotype 1 was significantly lower in AIA patients than in ATA patients in the dominant model (OR=0.25, <italic>P</italic>=0.04).</p></sec><sec><title>Conclusions</title><p>The +<italic>82466C&#x0003e;T</italic> polymorphism and haplotype 1 of the <italic>PPARG</italic> gene may be linked to increased risk for aspirin hypersensitivity in asthma.</p></sec></abstract><kwd-group><kwd>peroxisome proliferator-activated receptors gamma</kwd><kwd>aspirin</kwd><kwd>asthma</kwd><kwd>gene</kwd><kwd>polymorphism</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>INTRODUCTION</title><p>Peroxisome proliferator-activated receptors (PPARs) are transcriptional factors activated by ligands of the nuclear hormone receptor superfamily. This superfamily is divided into the steroid receptor family and the thyroid, vitamin D, and retinoid (or non-steroid) receptor family.<xref ref-type="bibr" rid="B1">1</xref> Three different PPAR subtypes have been identified: PPAR&#x003b1; (PPARA), PPAR&#x003b3; (<italic>PPARG</italic>), and PPAR&#x003b4; (PPARD, which is also called PPAR&#x003b2;). <italic>PPARG</italic> (MIM #601487), located on chromosome 3p25, plays an important role in regulating adipocyte differentiation and lipid metabolism<xref ref-type="bibr" rid="B2">2</xref> as well as cell turnover.<xref ref-type="bibr" rid="B3">3</xref> However, the production of immune-modulating cytokines in various cell types was reported to downregulate the expression of <italic>PPARG</italic>, and block adipocyte differentiation. It is well established that a variety of natural substances, including arachidonate pathway metabolites such as 15-hydroxyeicosatetranoic acid (15-HETE), strongly promote <italic>PPARG</italic> expression.<xref ref-type="bibr" rid="B3">3</xref>-<xref ref-type="bibr" rid="B5">5</xref> Stimulation of the <italic>PPARG</italic> ligand significantly inhibited the downregulation of eosinophil function.<xref ref-type="bibr" rid="B6">6</xref><italic>PPARG</italic> expression is associated with the inflammatory and remodeling responses in the asthmatic airway.<xref ref-type="bibr" rid="B7">7</xref></p><p>Among the sub-phenotypes of asthma, aspirin-intolerant asthma (AIA) refers to the development of bronchoconstriction in asthmatic individuals following the ingestion of aspirin or other non-steroidal anti-inflammatory drugs. This syndrome is characterized by the 'aspirin triad' of aspirin hypersensitivity, bronchial asthma, and nasal polyposis.<xref ref-type="bibr" rid="B8">8</xref> Most clinical investigators now include chronic hyperplastic eosinophilic sinusitis (CHES) as a fourth hallmark of aspirin-exacerbated respiratory disease (AERD).<xref ref-type="bibr" rid="B9">9</xref> As is true for other asthmatic individuals, the airways of patients with AIA show signs of persistent inflammation, with marked eosinophilia, epithelial disruption, cytokine production, and upregulation of inflammatory molecules.<xref ref-type="bibr" rid="B10">10</xref> Although the pathogenesis of AIA has not been elucidated completely, multiple points of overproduction or underproduction of critical mediators in the metabolism of arachidonic acid, including leukotrienes, lipoxins, thromboxane, and prostaglandins, probably account for the susceptibility to aspirin.<xref ref-type="bibr" rid="B10">10</xref> In addition, the levels of proinflammatory, immune cytokines and chemokines, including IL-2, IL-3, IL-4, IL-5, IL-13, GM-CSF, and eotaxin, are increased in the airways and systemic circulation in AIA.<xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B12">12</xref> The production of these molecules is regulated by various transcription factors, including <italic>PPARG</italic>. Therefore, genetic variants of the <italic>PPARG</italic> gene may be associated with the development of asthma or aspirin intolerance in asthmatics.</p><p>Recently, Palmer et al. reported that <italic>PPARG</italic> gene polymorphisms are associated with a risk for asthma exacerbation in Caucasian populations.<xref ref-type="bibr" rid="B13">13</xref> We also reported that the homozygous haplotype combination of +<italic>34C&#x0003e;G</italic> (Pro12Ala) was associated with an increased risk for asthma exacerbation.<xref ref-type="bibr" rid="B13">13</xref> To our knowledge, however, no study has analyzed the potential associations of the two common polymorphisms of the <italic>PPARG</italic> gene [+<italic>34C&#x0003e;G</italic> (Pro12Ala) and +<italic>82466C&#x0003e;T</italic> (His449His)] with the risk for aspirin intolerance in asthmatics.</p></sec><sec sec-type="methods"><title>MATERIALS AND METHODS</title><sec><title>Subjects</title><p>The subjects were recruited from the Asthma Genome Research Center, comprising Soonchunhyang Bucheon, Seoul, and Chunan Hospitals, and Chunnam and Chungbuk University Hospitals in Korea. All of the subjects were Korean. A clinical history was obtained for each patient, using a physician-administered questionnaire that included the history of aspirin hypersensitivity. The asthmatics had compatible clinical symptoms and physical characteristics (Global Initiative for Asthma).<xref ref-type="bibr" rid="B14">14</xref> All patients had a history of dyspnea and wheezing during the previous 12 months plus one of the following: 1) &#x0003e;15% increase in FEV<sub>1</sub> or &#x0003e;12% increase plus 200 mL following inhalation of a short-acting bronchodilator; 2) &#x0003c;10 mg/mL PC<sub>20</sub> methacholine; or 3) &#x0003e;20% increase in FEV<sub>1</sub> following 2 weeks of treatment with inhaled steroids and long-acting bronchodilators. The asthmatics had experienced no exacerbation of asthma or any respiratory tract infection in the 6 weeks preceding the oral aspirin challenge (OAC). Based on the results of the OAC, the asthmatics (n=403) were categorized into two groups: those with a decrease in FEV<sub>1</sub> of 15% or greater (AIA, n=60), and those with a decrease of less than 15% [aspirin-tolerant asthma (ATA), n=343]. The oral provocation test was performed with increasing doses of aspirin (10-450 mg Astrix; Mayne Pharma, Melbourne, Australia) using a modification of a previously described method.<xref ref-type="bibr" rid="B15">15</xref>,<xref ref-type="bibr" rid="B16">16</xref> Aspirin-intolerance bronchospasm, as reflected by the rate (%) of FEV<sub>1</sub> decline, was calculated as the difference between the pre-challenge and post-challenge FEV<sub>1</sub> values divided by the pre-challenge FEV<sub>1</sub>. Subjects who developed skin manifestations were labeled as positive responders (n=60). Normal controls (n=449) were recruited from among spouses of the patients or members of the general population who answered negatively to a screening questionnaire regarding respiratory symptoms.<xref ref-type="bibr" rid="B17">17</xref> The normal controls had no history of aspirin intolerance and had FEV<sub>1</sub> values &#x0003e;80% predicted, PC<sub>20</sub> methacholine &#x0003e;10 mg/mL, and normal findings on simple chest radiograms. Skin prick tests were performed with 24 common aeroallergens (Bencard, Brentford, UK). Atopy was defined as one or more positive reactions (&#x0003e;3 mm in diameter) on the skin prick test. Total IgE was measured using a UniCAP system (Pharmacia Diagnostics, Uppsala, Sweden). Subjects with diabetes mellitus were excluded because the <italic>PPARG</italic> polymorphism is reported to be associated with the development of diabetes mellitus in Koreans.<xref ref-type="bibr" rid="B18">18</xref> All subjects gave written informed consent to participate in the study, and the protocol was approved by the local ethics committees.</p></sec><sec><title>Genotyping the SNPs in the <italic>PPARG</italic> gene</title><p>The amplifying primers and probes used to genotype the polymorphic sites by the single base method were as described previously.<xref ref-type="bibr" rid="B19">19</xref> Primer Express (Applied Biosystems, Foster City, CA, USA) was used to design the PCR primers and MGB TaqMan probes. One allelic probe was labeled with FAM dye; and the other, with fluorescent VIC dye. PCR was performed in TaqMan Universal Master Mix, without uracil-N-glycosylase (Applied Biosystems), containing 900 nM TaqMan MGB-probe and 200 nM primer. The reaction was performed in a 384-well plate in a total reaction volume of 5 &#x000b5;L, using 20 ng of genomic DNA. The plate was heated in a thermal cycler (PE 9700; Applied Biosystems) for 2 min at 50&#x02103; and then for 10 min at 95&#x02103;, followed by 40 cycles of 95&#x02103; for 15 s and 60&#x02103; for 1 min. The fluorescence intensity of each reaction was determined using a Prism 7900 HT detector (Applied Biosystems), and the fluorescence data were analyzed by automated software (SDS 2.1).</p></sec><sec><title>Statistical analysis</title><p>We applied the widely used Lewontin's D' (|D'|) and <italic>R<sup>2</sup></italic> measures of linkage disequilibrium to all pairs of biallelic loci.<xref ref-type="bibr" rid="B20">20</xref> Haplotype associations were estimated using HaploScore (<ext-link ext-link-type="uri" xlink:href="http://www.biostat.wustl.edu/genetics/geneticssoft/">http://www.biostat.wustl.edu/genetics/geneticssoft/</ext-link>), which computes score statistics to test for associations between a given haplotype and a wide variety of traits, including binary, ordinal, quantitative, and Poisson parameters. The genetic effects of the haplotypes were analyzed in the same way as the SNPs. The distributions of the <italic>PPARG</italic> SNP genotypes and haplotypes among the subjects with asthma and the normal subjects were analyzed with logistic regression models that controlled for age (continuous value), gender (male=0, female=1), atopy status (non-atopy=0, atopy=1), body mass index (BMI; continuous value), and smoking status (nonsmoker=0, ex-smoker=1, smoker=2) as covariates. The data were managed and analyzed using SPSS ver. 10.0 (SPSS, Chicago, IL, USA). A value of <italic>P</italic>&#x02264;0.05 was regarded as statistically significant.</p></sec></sec><sec sec-type="results"><title>RESULTS</title><sec><title>Characteristics of the study subjects</title><p>We recruited 403 subjects from the asthma cohort. The clinical characteristics of the study subjects are summarized in <xref ref-type="table" rid="T1">Table 1</xref>. The maximum fall in FEV<sub>1</sub> during the 5-hr follow-up period after aspirin challenge was used as the value for the aspirin-induced fall in FEV<sub>1</sub>. Aspirin-induced declines in FEV<sub>1</sub> ranged from -15% to 68%. The log transformed PC<sub>20</sub> methacholine values for the asthmatics were significantly lower among those with AIA than among those with ATA (<italic>P</italic>=0.013, <xref ref-type="table" rid="T1">Table 1</xref>).</p></sec><sec><title><italic>PPARG</italic> polymorphisms and the risk for aspirin intolerance in asthmatics</title><p>Two SNPs, +<italic>34C&#x0003e;G</italic> (P12A) on exon 3 and +<italic>82466C&#x0003e;T</italic> (H449H) on exon 8, in the <italic>PPARG</italic> gene were genotyped for the association study. The minor allele frequencies (MAFs) of these two SNPs in the Korean population were 0.042 (+<italic>34C&#x0003e;G</italic>) and 0.168 (+<italic>82466C&#x0003e;T</italic>) (<xref ref-type="table" rid="T2">Table 2</xref>). The genotype distributions of the two SNPs were in Hardy-Weinberg equilibrium for all subjects (<italic>P</italic>&#x0003e;0.05, <xref ref-type="table" rid="T2">Table 2</xref>). Four haplotypes were constructed, and two haplotypes with a frequency &#x0003e;0.05 were used for the analysis. Using multiple logistic regression models, both SNPs and the two haplotypes (<italic>ht1</italic> and <italic>ht2</italic>) were analyzed for associations with the risk for aspirin intolerance in the asthmatics (<xref ref-type="table" rid="T3">Table 3</xref>). The analysis revealed that <italic>PPARG</italic>+<italic>82466C&#x0003e;T</italic> was associated with aspirin intolerance in the recessive model, and there were more subjects homozygous for the rare alleles <italic>PPARG</italic>+<italic>82466C&#x0003e;T</italic> in the AIA group than in the ATA group in the recessive model (6.66% vs. 2.04%, <italic>P</italic>=0.04, OR=3.97 [1.08-14.53]). In the haplotype analysis, there were fewer subjects with <italic>ht1</italic> in the AIA group than in the ATA group (93.33% vs. 97.96%, <italic>P</italic>=0.04, OR=0.25 [0.07-0.92]) in the dominant model. The rate (%) of FEV<sub>1</sub> decline after aspirin challenge is the most important parameter for the diagnosis of aspirin intolerant asthmatics, and thus we used linear regression analysis to investigate the associations between the SNP (+<italic>82466C&#x0003e;T</italic>), haplotype 1, and percentage fall of FEV<sub>1</sub> following aspirin challenge. Haplotype 1 and +<italic>82466C&#x0003e;T</italic> showed the strongest association with the rate (%) of FEV<sub>1</sub> decline after aspirin challenge in the asthmatics. Asthmatics homozygous for the rare +<italic>82466C&#x0003e;T</italic> allele had a greater decline in FEV<sub>1</sub> after aspirin provocation than those with the common allele (<italic>P</italic>=0.0004, <xref ref-type="fig" rid="F1">Fig. 1A</xref>). In the haplotype analysis, the decline in FEV<sub>1</sub> after aspirin provocation was greater in asthmatics lacking the <italic>ht1</italic> haplotype than in those with the haplotype (<italic>P</italic>=0.0004, <xref ref-type="fig" rid="F1">Fig. 1B</xref>).</p></sec></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>PPARs are receptors for steroids, thyroid hormone, vitamin D, and retinoic acid,<xref ref-type="bibr" rid="B1">1</xref> and they regulate adipocyte differentiation, lipid metabolism,<xref ref-type="bibr" rid="B2">2</xref> and cellular turnover.<xref ref-type="bibr" rid="B3">3</xref> Furthermore, polymorphisms of the <italic>PPARG</italic> gene have been associated with diabetes, obesity, and metabolic syndrome.<xref ref-type="bibr" rid="B18">18</xref>,<xref ref-type="bibr" rid="B21">21</xref>-<xref ref-type="bibr" rid="B25">25</xref> The two common polymorphisms of <italic>PPARG</italic> were reported to modify susceptibility to type II diabetes mellitus, obesity, and sub-phenotypes of metabolic syndrome in Koreans<xref ref-type="bibr" rid="B18">18</xref>,<xref ref-type="bibr" rid="B21">21</xref>,<xref ref-type="bibr" rid="B22">22</xref> and Caucasians.<xref ref-type="bibr" rid="B23">23</xref>-<xref ref-type="bibr" rid="B26">26</xref> Therefore, we excluded subjects with diabetes from the analysis and adjusted the results for the BMI.</p><p>In addition to their metabolic effects, PPARs/RXRs heterodimerize with various receptors, and these heterodimers regulate the transcription of genes involved in allergic inflammation and airway remodeling.<xref ref-type="bibr" rid="B7">7</xref> A notable finding in our study was that the SNP <italic>PPARG</italic>+<italic>82466C&#x0003e;T</italic> was associated with aspirin intolerance. There were more subjects homozygous for the rare <italic>PPARG</italic>+<italic>82466C&#x0003e;T</italic> allele with AIA than with ATA in the recessive model (<xref ref-type="table" rid="T3">Table 3</xref>). In the haplotype analysis, there were significantly fewer subjects with <italic>ht1</italic> in the AIA group than in the ATA group. Based on linear regression analysis, the decline in FEV<sub>1</sub> after aspirin challenge in asthmatics homozygous for the rare +<italic>82466C&#x0003e;T</italic> allele was 2.5 times that in asthmatics with the common allele. In the haplotype analysis, the decline in FEV<sub>1</sub> after aspirin provocation was greater in asthmatics without the <italic>ht1</italic> haplotype than in those with the haplotype. These results suggest that a rare <italic>PPARG</italic>+<italic>82466C&#x0003e;T</italic> allele and haplotype 1 are predisposing factors for aspirin intolerance in asthmatics.</p><p>Some eicosanoids activate <italic>PPARG</italic>; these include 13-hydroxyoctadecadienoic acid,<xref ref-type="bibr" rid="B27">27</xref> 15-hydroxyeicosatetraenoic acid (15-HETE), and 15-deoxy-12,14 prostaglandinJ2 (15d-PGJ 2),<xref ref-type="bibr" rid="B28">28</xref> a prostaglandin D2 metabolite. The accumulation of 15-HETE after aspirin-stimulation of peripheral leukocytes from patients with AIA may activate <italic>PPARG</italic> to modulate airway inflammation.<xref ref-type="bibr" rid="B29">29</xref> As metabolites of the arachidonate pathway, such as 15-HETE and 15d-PGJ 2, regulate transcription and endogenous ligands for the <italic>PPARG</italic> gene, changes in these mediators in AIA may be responsible for the change in the amount of PPAR-r in the target organ of aspirin hypersensitivity. Therefore, altered synthesis of 15-HETE and 15d-PGJ 2 in AIA may activate <italic>PPARG</italic> differently from the activation in ATA. In addition, the <italic>PPARG</italic> agonist rosiglitazone upregulates both the mRNA expression of two lipoxygenase enzymes (platelet-type 12-lipoxygenase and 15-lipoxygenase) and the secretion of their eicosanoid products, 12- and 15-HETE. The rosiglitazone-induced increase in <italic>PPARG</italic> mRNA expression is blocked entirely by the lipoxygenase (LO) inhibitor baicalein and is restored by the addition of exogenous 12-HETE.<xref ref-type="bibr" rid="B30">30</xref> In the process of lipoxin formation, aspirin acetylation does not totally inhibit the catalysis of COX-2, and this can affect the production of 12-HETE, 15-HETE, and 13-HODE. Previously, we observed that the alleles of the ALOX5 and ALOX5AP promoters cannot be considered prominent risk factors for the development of AIA. However, a genetic variant involving a tandem repeat (GGGCGG; Sp1-binding motif) in the ALOX5 promoter is associated with the severity of airway hyper-responsiveness in AIA patients.<xref ref-type="bibr" rid="B31">31</xref> Therefore, genetic polymorphism of the rare <italic>PPARG</italic>+<italic>82466C&#x0003e;T</italic> allele may contribute to the development of aspirin intolerance via a functional change in the gene, such as an altered response to the LO products or altered induction of the two LO enzymes. The molecular mechanism by which the rare <italic>PPARG</italic>+<italic>82466C&#x0003e;T</italic> allele, which does not change the encoded protein, modulates the phenotype is even less clear. It is possible that these variants are in linkage disequilibrium with other functional variants, although the <italic>PPARG</italic> locus has been the focus of intense scrutiny as a candidate for diabetes and related traits, and no such variant has been found.</p><p>In summary, we genotyped two SNPs in the <italic>PPARG</italic> gene, +<italic>34C&#x0003e;G</italic> (Pro12Ala) and +<italic>82466C&#x0003e;T</italic> (His449His), and examined the association of each with the development of aspirin intolerance in asthmatics. Association analysis showed that <italic>PPARG</italic>+<italic>82466C&#x0003e;T</italic> and <italic>PPARG</italic> haplotypes were associated with the development of aspirin intolerance. Therefore, the +<italic>82466C&#x0003e;T</italic> polymorphism in the coding region of the <italic>PPARG</italic> gene may confer aspirin hypersensitivity via the regulation of gene expression. This information may be useful in the development of new strategies for the diagnosis and control of aspirin intolerance. Further studies are required to define the molecular mechanisms by which common variation at the <italic>PPARG</italic> locus modulates aspirin hypersensitivity, and to determine whether this suggests treatment strategies in asthmatics with different <italic>PPARG</italic> genotypes.</p></sec></body><back><ack><title>ACKNOWLEDGMENTS</title><p>This work was supported by a grant from the <funding-source>Korea Health 21 R&#x00026;D Project</funding-source>, (<award-id>A010249</award-id>), and the DNA samples were generously provided by the Soonchunhyang University Bucheon Hospital Biobank, a member of the National Biobank of Korea, supported by the <funding-source>Ministry of Health, Welfare, and Family Affairs, Republic of Korea</funding-source>.</p></ack><fn-group><fn fn-type="conflict"><p>There are no financial or other issues that might lead to conflict of interest.</p></fn></fn-group><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mangelsdorf</surname><given-names>DJ</given-names></name><name><surname>Thummel</surname><given-names>C</given-names></name><name><surname>Beato</surname><given-names>M</given-names></name><name><surname>Herrlich</surname><given-names>P</given-names></name><name><surname>Sch&#x000fc;tz</surname><given-names>G</given-names></name><name><surname>Umesono</surname><given-names>K</given-names></name><name><surname>Blumberg</surname><given-names>B</given-names></name><name><surname>Kastner</surname><given-names>P</given-names></name><name><surname>Mark</surname><given-names>M</given-names></name><name><surname>Chambon</surname><given-names>P</given-names></name><name><surname>Evans</surname><given-names>RM</given-names></name></person-group><article-title>The nuclear receptor superfamily: the second decade</article-title><source>Cell</source><year>1995</year><volume>83</volume><fpage>835</fpage><lpage>839</lpage><pub-id pub-id-type="pmid">8521507</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tontonoz</surname><given-names>P</given-names></name><name><surname>Hu</surname><given-names>E</given-names></name><name><surname>Spiegelman</surname><given-names>BM</given-names></name></person-group><article-title>Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor</article-title><source>Cell</source><year>1994</year><volume>79</volume><fpage>1147</fpage><lpage>1156</lpage><pub-id pub-id-type="pmid">8001151</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chinetti</surname><given-names>G</given-names></name><name><surname>Griglio</surname><given-names>S</given-names></name><name><surname>Antonucci</surname><given-names>M</given-names></name><name><surname>Torra</surname><given-names>IP</given-names></name><name><surname>Delerive</surname><given-names>P</given-names></name><name><surname>Majd</surname><given-names>Z</given-names></name><name><surname>Fruchart</surname><given-names>JC</given-names></name><name><surname>Chapman</surname><given-names>J</given-names></name><name><surname>Najib</surname><given-names>J</given-names></name><name><surname>Staels</surname><given-names>B</given-names></name></person-group><article-title>Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages</article-title><source>J Biol Chem</source><year>1998</year><volume>273</volume><fpage>25573</fpage><lpage>25580</lpage><pub-id pub-id-type="pmid">9748221</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>C</given-names></name><name><surname>Ting</surname><given-names>AT</given-names></name><name><surname>Seed</surname><given-names>B</given-names></name></person-group><article-title>PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines</article-title><source>Nature</source><year>1998</year><volume>391</volume><fpage>82</fpage><lpage>86</lpage><pub-id pub-id-type="pmid">9422509</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>JT</given-names></name><name><surname>Welch</surname><given-names>JS</given-names></name><name><surname>Ricote</surname><given-names>M</given-names></name><name><surname>Binder</surname><given-names>CJ</given-names></name><name><surname>Willson</surname><given-names>TM</given-names></name><name><surname>Kelly</surname><given-names>C</given-names></name><name><surname>Witztum</surname><given-names>JL</given-names></name><name><surname>Funk</surname><given-names>CD</given-names></name><name><surname>Conrad</surname><given-names>D</given-names></name><name><surname>Glass</surname><given-names>CK</given-names></name></person-group><article-title>Interleukin-4-dependent production of PPAR-gamma ligands in macrophages by 12/15-lipoxygenase</article-title><source>Nature</source><year>1999</year><volume>400</volume><fpage>378</fpage><lpage>382</lpage><pub-id pub-id-type="pmid">10432118</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ueki</surname><given-names>S</given-names></name><name><surname>Matsuwaki</surname><given-names>Y</given-names></name><name><surname>Kayaba</surname><given-names>H</given-names></name><name><surname>Oyamada</surname><given-names>H</given-names></name><name><surname>Kanda</surname><given-names>A</given-names></name><name><surname>Usami</surname><given-names>A</given-names></name><name><surname>Saito</surname><given-names>N</given-names></name><name><surname>Chihara</surname><given-names>J</given-names></name></person-group><article-title>Peroxisome proliferator-activated receptor gamma regulates eosinophil functions: a new therapeutic target for allergic airway inflammation</article-title><source>Int Arch Allergy Immunol</source><year>2004</year><volume>134</volume><issue>Suppl 1</issue><fpage>30</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">15166481</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benayoun</surname><given-names>L</given-names></name><name><surname>Letuve</surname><given-names>S</given-names></name><name><surname>Druilhe</surname><given-names>A</given-names></name><name><surname>Boczkowski</surname><given-names>J</given-names></name><name><surname>Dombret</surname><given-names>MC</given-names></name><name><surname>Mechighel</surname><given-names>P</given-names></name><name><surname>Megret</surname><given-names>J</given-names></name><name><surname>Leseche</surname><given-names>G</given-names></name><name><surname>Aubier</surname><given-names>M</given-names></name><name><surname>Pretolani</surname><given-names>M</given-names></name></person-group><article-title>Regulation of peroxisome proliferator-activated receptor gamma expression in human asthmatic airways: relationship with proliferation, apoptosis, and airway remodeling</article-title><source>Am J Respir Crit Care Med</source><year>2001</year><volume>164</volume><fpage>1487</fpage><lpage>1494</lpage><pub-id pub-id-type="pmid">11704601</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Samter</surname><given-names>M</given-names></name><name><surname>Beers</surname><given-names>RF</given-names><suffix>Jr</suffix></name></person-group><article-title>Concerning the nature of intolerance to aspirin</article-title><source>J Allergy</source><year>1967</year><volume>40</volume><fpage>281</fpage><lpage>293</lpage><pub-id pub-id-type="pmid">5235203</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stevenson</surname><given-names>DD</given-names></name><name><surname>Sanchez-Borges</surname><given-names>M</given-names></name><name><surname>Szczeklik</surname><given-names>A</given-names></name></person-group><article-title>Classification of allergic and pseudoallergic reactions to drugs that inhibit cyclooxygenase enzymes</article-title><source>Ann Allergy Asthma Immunol</source><year>2001</year><volume>87</volume><fpage>177</fpage><lpage>180</lpage><pub-id pub-id-type="pmid">11570612</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szczeklik</surname><given-names>A</given-names></name><name><surname>Stevenson</surname><given-names>DD</given-names></name></person-group><article-title>Aspirin-induced asthma: advances in pathogenesis, diagnosis, and management</article-title><source>J Allergy Clin Immunol</source><year>2003</year><volume>111</volume><fpage>913</fpage><lpage>921</lpage><pub-id pub-id-type="pmid">12743549</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bachert</surname><given-names>C</given-names></name><name><surname>Wagenmann</surname><given-names>M</given-names></name><name><surname>Hauser</surname><given-names>U</given-names></name><name><surname>Rudack</surname><given-names>C</given-names></name></person-group><article-title>IL-5 synthesis is upregulated in human nasal polyp tissue</article-title><source>J Allergy Clin Immunol</source><year>1997</year><volume>99</volume><fpage>837</fpage><lpage>842</lpage><pub-id pub-id-type="pmid">9215253</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Min</surname><given-names>JW</given-names></name><name><surname>Jang</surname><given-names>AS</given-names></name><name><surname>Park</surname><given-names>SM</given-names></name><name><surname>Lee</surname><given-names>SH</given-names></name><name><surname>Lee</surname><given-names>JH</given-names></name><name><surname>Park</surname><given-names>SW</given-names></name><name><surname>Park</surname><given-names>CS</given-names></name></person-group><article-title>Comparison of plasma eotaxin family level in aspirin-induced and aspirin-tolerant asthma patients</article-title><source>Chest</source><year>2005</year><volume>128</volume><fpage>3127</fpage><lpage>3132</lpage><pub-id pub-id-type="pmid">16304252</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palmer</surname><given-names>CN</given-names></name><name><surname>Doney</surname><given-names>AS</given-names></name><name><surname>Ismail</surname><given-names>T</given-names></name><name><surname>Lee</surname><given-names>SP</given-names></name><name><surname>Murrie</surname><given-names>I</given-names></name><name><surname>Macgregor</surname><given-names>DF</given-names></name><name><surname>Mukhopadhyay</surname><given-names>S</given-names></name></person-group><article-title>PPARG locus haplotype variation and exacerbations in asthma</article-title><source>Clin Pharmacol Ther</source><year>2007</year><volume>81</volume><fpage>713</fpage><lpage>718</lpage><pub-id pub-id-type="pmid">17329993</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><collab>National Asthma Education and Prevention Program</collab><article-title>Expert panel report: guidelines for the diagnosis and management of asthma update on selected topics</article-title><source>J Allergy Clin Immunol</source><year>2002</year><volume>110</volume><fpage>S141</fpage><lpage>S219</lpage><pub-id pub-id-type="pmid">12542074</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>TH</given-names></name><name><surname>Chang</surname><given-names>HS</given-names></name><name><surname>Park</surname><given-names>SM</given-names></name><name><surname>Nam</surname><given-names>BY</given-names></name><name><surname>Park</surname><given-names>JS</given-names></name><name><surname>Rhim</surname><given-names>T</given-names></name><name><surname>Park</surname><given-names>HS</given-names></name><name><surname>Kim</surname><given-names>MK</given-names></name><name><surname>Choi</surname><given-names>IS</given-names></name><name><surname>Cho</surname><given-names>SH</given-names></name><name><surname>Chung</surname><given-names>IY</given-names></name><name><surname>Park</surname><given-names>BL</given-names></name><name><surname>Park</surname><given-names>CS</given-names></name><name><surname>Shin</surname><given-names>HD</given-names></name></person-group><article-title>Association of angiotensin I-converting enzyme gene polymorphisms with aspirin intolerance in asthmatics</article-title><source>Clin Exp Allergy</source><year>2008</year><volume>38</volume><fpage>1727</fpage><lpage>1737</lpage><pub-id pub-id-type="pmid">18727619</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cormican</surname><given-names>LJ</given-names></name><name><surname>Farooque</surname><given-names>S</given-names></name><name><surname>Altmann</surname><given-names>DR</given-names></name><name><surname>Lee</surname><given-names>TH</given-names></name></person-group><article-title>Improvements in an oral aspirin challenge protocol for the diagnosis of aspirin hypersensitivity</article-title><source>Clin Exp Allergy</source><year>2005</year><volume>35</volume><fpage>717</fpage><lpage>722</lpage><pub-id pub-id-type="pmid">15969660</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferris</surname><given-names>BG</given-names></name></person-group><article-title>Epidemiology Standardization Project (American Thoracic Society)</article-title><source>Am Rev Respir Dis</source><year>1978</year><volume>118</volume><fpage>1</fpage><lpage>120</lpage><pub-id pub-id-type="pmid">742764</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moon</surname><given-names>MK</given-names></name><name><surname>Cho</surname><given-names>YM</given-names></name><name><surname>Jung</surname><given-names>HS</given-names></name><name><surname>Park</surname><given-names>YJ</given-names></name><name><surname>Yoon</surname><given-names>KH</given-names></name><name><surname>Sung</surname><given-names>YA</given-names></name><name><surname>Park</surname><given-names>BL</given-names></name><name><surname>Lee</surname><given-names>HK</given-names></name><name><surname>Park</surname><given-names>KS</given-names></name><name><surname>Shin</surname><given-names>HD</given-names></name></person-group><article-title>Genetic polymorphisms in peroxisome proliferator-activated receptor gamma are associated with Type 2 diabetes mellitus and obesity in the Korean population</article-title><source>Diabet Med</source><year>2005</year><volume>22</volume><fpage>1161</fpage><lpage>1166</lpage><pub-id pub-id-type="pmid">16108843</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oh</surname><given-names>SH</given-names></name><name><surname>Park</surname><given-names>SM</given-names></name><name><surname>Lee</surname><given-names>YH</given-names></name><name><surname>Cha</surname><given-names>JY</given-names></name><name><surname>Lee</surname><given-names>JY</given-names></name><name><surname>Shin</surname><given-names>EK</given-names></name><name><surname>Park</surname><given-names>JS</given-names></name><name><surname>Park</surname><given-names>BL</given-names></name><name><surname>Shin</surname><given-names>HD</given-names></name><name><surname>Park</surname><given-names>CS</given-names></name></person-group><article-title>Association of peroxisome proliferator-activated receptor-gamma gene polymorphisms with the development of asthma</article-title><source>Respir Med</source><year>2009</year><volume>103</volume><fpage>1020</fpage><lpage>1024</lpage><pub-id pub-id-type="pmid">19217272</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hedrick</surname><given-names>PW</given-names></name></person-group><article-title>Gametic disequilibrium measures: proceed with caution</article-title><source>Genetics</source><year>1987</year><volume>117</volume><fpage>331</fpage><lpage>341</lpage><pub-id pub-id-type="pmid">3666445</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>KS</given-names></name><name><surname>Choi</surname><given-names>SM</given-names></name><name><surname>Shin</surname><given-names>SU</given-names></name><name><surname>Yang</surname><given-names>HS</given-names></name><name><surname>Yoon</surname><given-names>Y</given-names></name></person-group><article-title>Effects of peroxisome proliferator-activated receptor-gamma 2 Pro12Ala polymorphism on body fat distribution in female Korean subjects</article-title><source>Metabolism</source><year>2004</year><volume>53</volume><fpage>1538</fpage><lpage>1543</lpage><pub-id pub-id-type="pmid">15562396</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rhee</surname><given-names>EJ</given-names></name><name><surname>Oh</surname><given-names>KW</given-names></name><name><surname>Lee</surname><given-names>WY</given-names></name><name><surname>Kim</surname><given-names>SY</given-names></name><name><surname>Oh</surname><given-names>ES</given-names></name><name><surname>Baek</surname><given-names>KH</given-names></name><name><surname>Kang</surname><given-names>MI</given-names></name><name><surname>Kim</surname><given-names>SW</given-names></name></person-group><article-title>Effects of two common polymorphisms of peroxisome proliferator-activated receptor-gamma gene on metabolic syndrome</article-title><source>Arch Med Res</source><year>2006</year><volume>37</volume><fpage>86</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">16314192</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doney</surname><given-names>AS</given-names></name><name><surname>Fischer</surname><given-names>B</given-names></name><name><surname>Cecil</surname><given-names>JE</given-names></name><name><surname>Boylan</surname><given-names>K</given-names></name><name><surname>McGuigan</surname><given-names>FE</given-names></name><name><surname>Ralston</surname><given-names>SH</given-names></name><name><surname>Morris</surname><given-names>AD</given-names></name><name><surname>Palmer</surname><given-names>CN</given-names></name></person-group><article-title>Association of the Pro12Ala and C1431T variants of PPARG and their haplotypes with susceptibility to Type 2 diabetes</article-title><source>Diabetologia</source><year>2004</year><volume>47</volume><fpage>555</fpage><lpage>558</lpage><pub-id pub-id-type="pmid">14730381</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Altshuler</surname><given-names>D</given-names></name><name><surname>Hirschhorn</surname><given-names>JN</given-names></name><name><surname>Klannemark</surname><given-names>M</given-names></name><name><surname>Lindgren</surname><given-names>CM</given-names></name><name><surname>Vohl</surname><given-names>MC</given-names></name><name><surname>Nemesh</surname><given-names>J</given-names></name><name><surname>Lane</surname><given-names>CR</given-names></name><name><surname>Schaffner</surname><given-names>SF</given-names></name><name><surname>Bolk</surname><given-names>S</given-names></name><name><surname>Brewer</surname><given-names>C</given-names></name><name><surname>Tuomi</surname><given-names>T</given-names></name><name><surname>Gaudet</surname><given-names>D</given-names></name><name><surname>Hudson</surname><given-names>TJ</given-names></name><name><surname>Daly</surname><given-names>M</given-names></name><name><surname>Groop</surname><given-names>L</given-names></name><name><surname>Lander</surname><given-names>ES</given-names></name></person-group><article-title>The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes</article-title><source>Nat Genet</source><year>2000</year><volume>26</volume><fpage>76</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">10973253</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ardlie</surname><given-names>KG</given-names></name><name><surname>Lunetta</surname><given-names>KL</given-names></name><name><surname>Seielstad</surname><given-names>M</given-names></name></person-group><article-title>Testing for population subdivision and association in four case-control studies</article-title><source>Am J Hum Genet</source><year>2002</year><volume>71</volume><fpage>304</fpage><lpage>311</lpage><pub-id pub-id-type="pmid">12096349</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buzzetti</surname><given-names>R</given-names></name><name><surname>Petrone</surname><given-names>A</given-names></name><name><surname>Ribaudo</surname><given-names>MC</given-names></name><name><surname>Alemanno</surname><given-names>I</given-names></name><name><surname>Zavarella</surname><given-names>S</given-names></name><name><surname>Mein</surname><given-names>CA</given-names></name><name><surname>Maiani</surname><given-names>F</given-names></name><name><surname>Tiberti</surname><given-names>C</given-names></name><name><surname>Baroni</surname><given-names>MG</given-names></name><name><surname>Vecci</surname><given-names>E</given-names></name><name><surname>Arca</surname><given-names>M</given-names></name><name><surname>Leonetti</surname><given-names>F</given-names></name><name><surname>Di Mario</surname><given-names>U</given-names></name></person-group><article-title>The common PPAR-gamma2 Pro12Ala variant is associated with greater insulin sensitivity</article-title><source>Eur J Hum Genet</source><year>2004</year><volume>12</volume><fpage>1050</fpage><lpage>1054</lpage><pub-id pub-id-type="pmid">15367918</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagy</surname><given-names>L</given-names></name><name><surname>Tontonoz</surname><given-names>P</given-names></name><name><surname>Alvarez</surname><given-names>JG</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Evans</surname><given-names>RM</given-names></name></person-group><article-title>Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma</article-title><source>Cell</source><year>1998</year><volume>93</volume><fpage>229</fpage><lpage>240</lpage><pub-id pub-id-type="pmid">9568715</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Forman</surname><given-names>BM</given-names></name><name><surname>Tontonoz</surname><given-names>P</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Brun</surname><given-names>RP</given-names></name><name><surname>Spiegelman</surname><given-names>BM</given-names></name><name><surname>Evans</surname><given-names>RM</given-names></name></person-group><article-title>15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma</article-title><source>Cell</source><year>1995</year><volume>83</volume><fpage>803</fpage><lpage>812</lpage><pub-id pub-id-type="pmid">8521497</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kowalski</surname><given-names>ML</given-names></name><name><surname>Ptasinska</surname><given-names>A</given-names></name><name><surname>Bienkiewicz</surname><given-names>B</given-names></name><name><surname>Pawliczak</surname><given-names>R</given-names></name><name><surname>DuBuske</surname><given-names>L</given-names></name></person-group><article-title>Differential effects of aspirin and misoprostol on 15-hydroxyeicosatetraenoic acid generation by leukocytes from aspirin-sensitive asthmatic patients</article-title><source>J Allergy Clin Immunol</source><year>2003</year><volume>112</volume><fpage>505</fpage><lpage>512</lpage><pub-id pub-id-type="pmid">13679808</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Limor</surname><given-names>R</given-names></name><name><surname>Sharon</surname><given-names>O</given-names></name><name><surname>Knoll</surname><given-names>E</given-names></name><name><surname>Many</surname><given-names>A</given-names></name><name><surname>Weisinger</surname><given-names>G</given-names></name><name><surname>Stern</surname><given-names>N</given-names></name></person-group><article-title>Lipoxygenase-derived metabolites are regulators of peroxisome proliferator-activated receptor gamma-2 expression in human vascular smooth muscle cells</article-title><source>Am J Hypertens</source><year>2008</year><volume>21</volume><fpage>219</fpage><lpage>223</lpage><pub-id pub-id-type="pmid">18202670</pub-id></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>SH</given-names></name><name><surname>Bae</surname><given-names>JS</given-names></name><name><surname>Suh</surname><given-names>CH</given-names></name><name><surname>Nahm</surname><given-names>DH</given-names></name><name><surname>Holloway</surname><given-names>JW</given-names></name><name><surname>Park</surname><given-names>HS</given-names></name></person-group><article-title>Polymorphism of tandem repeat in promoter of 5-lipoxygenase in ASA-intolerant asthma: a positive association with airway hyperresponsiveness</article-title><source>Allergy</source><year>2005</year><volume>60</volume><fpage>760</fpage><lpage>765</lpage><pub-id pub-id-type="pmid">15876305</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="F1" position="float"><label>Fig. 1</label><caption><p>The comparison of the rate of fall (%) of FEV<sub>1</sub> with aspirin provocation between subjects possessing the rare and common alleles by (A) +<italic>82466C&#x0003e;T</italic> and (B) haplotype 1 of <italic>PPARG</italic> gene. The <italic>P</italic> values were obtained by linear regression analysis, controlled for age (continuous value), gender (male=0, female=1), atopy status (non-atopy=0, atopy=1), smoking status (non-smoker=0, ex-smoker=1, smoker=2), and BMI (continuous value) as covariates.</p></caption><graphic xlink:href="aair-1-30-g001"/></fig><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>The clinical profiles of the study subjects</p></caption><graphic xlink:href="aair-1-30-i001"/><table-wrap-foot><fn><p>Values are mean&#x000b1;S.E. ATA and AIA represent aspirin-tolerant asthma and aspirin-intolerant asthma, respectively.</p><p><italic>P</italic> values are obtained using T test or &#x003c7;<sup>2</sup> test between AIA and ATA.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>The frequencies, heterozygosity and Hardy-Weinberg Equation of SNPs on <italic>PPARG</italic> gene in the study population</p></caption><graphic xlink:href="aair-1-30-i002"/><table-wrap-foot><fn><p>C/C, C/R and C/C represent common allele, heterozygosity and rare allele.</p><p><sup>*</sup><italic>P</italic> values of deviation from Hardy-Weinberg Equilibrium in the study population.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T3" position="float"><label>Table 3</label><caption><p>Comparisons of genotype and haplotype distributions of <italic>PPARG</italic> between the subjects with AIA and the subjects with ATA</p></caption><graphic xlink:href="aair-1-30-i003"/><table-wrap-foot><fn><p>ATA and AIA represent aspirin-tolerant asthma and aspirin-intolerant asthma, respectively. C/C, C/R and R/R represent common allele, heterozygosity and rare allele. The <italic>P</italic> values were obtained by logistic regression analysis, controlled for age (continuous value), sex (male=0, female=1), atopy status (non-atopy=0, atopy=1) and smoking status (non-smoker=0, ex-smoker=1, smoker=2) and BMI (continuous value) as co-variables.</p><p>Bold faces mean the <italic>P</italic>&#x0003c;0.05.</p></fn></table-wrap-foot></table-wrap></floats-group></article>